Welcome to our dedicated page for Vivos SEC filings (Ticker: RDGL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Vivos Inc’s SEC disclosures are packed with technical details on Yttrium-90 Radiogel trials, isotope supply chains, and FDA interactions—crucial data that can run hundreds of pages. Finding the exact section on clinical results or executive stock sales often feels like searching for a micro-dose in a radiology lab.
Stock Titan’s AI-powered analysis turns those dense documents into clear takeaways. Whether you need the Vivos Inc quarterly earnings report 10-Q filing for burn-rate trends, the Vivos Inc annual report 10-K simplified for regulatory hurdles, or an 8-K material events explained alert when new trial data drops, our platform highlights the numbers and narratives that matter. Real-time monitoring pushes Vivos Inc Form 4 insider transactions to your dashboard the moment they hit EDGAR, so you can track executive confidence without refreshing pages.
Common investor questions are answered right here: “How do I read Vivos Inc SEC filings explained simply?” “Where can I see Vivos Inc insider trading Form 4 transactions?” “What compensation details appear in the Vivos Inc proxy statement executive compensation report?” From clinical milestone timelines buried in MD&A sections to Vivos Inc earnings report filing analysis of segment spending, our AI surfaces the insights in seconds.
Stop paging through appendices. Use Stock Titan to compare quarter-over-quarter R&D spend, monitor Vivos Inc executive stock transactions Form 4 in real-time, and understand FDA correspondence disclosed across filings—all in one decisive view.
Vivos Inc (RDGL) reported Q3 2025 results. For the nine months ended September 30, 2025, revenue was $43,627 versus $23,000 a year ago, while Q3 revenue was $1,879 versus $5,000. The company posted a nine‑month operating loss of $2,069,328 and a net loss of $1,987,503.
Cash was $2,202,109 as of September 30, 2025. Operating cash use totaled $1,518,189 for the period, partially offset by $1,507,750 from financing activities, including $1,506,250 raised via a Regulation A+ equity issuance and related warrants. Shares outstanding were 454,664,957 as of November 11, 2025.
Management disclosed substantial doubt about the company’s ability to continue as a going concern and estimates it requires approximately $3.0 million annually to maintain operations and about $9.0 million over 36 months for clinical and commercialization plans. The Board approved Vivos Scientific India LLP on September 17, 2025, established October 1, 2025, to support manufacturing and human therapy initiatives.
FAQ
What is the current stock price of Vivos (RDGL)?
What is the market cap of Vivos (RDGL)?
